The use of cannabinoids in epilepsy as an example: medical, social, and legal aspects
Abstract
The review provides historical information on the medical use of cannabinoids from antiquity to the present day. It presents the most common indications for their use in neurology, oncology, and psychiatry for the treatment of social diseases, such as epilepsy, pain syndromes, spasticity, including multiple sclerosis, Parkinson's disease, depression, schizophrenia, dementia, etc. There are data of the largest-scale and evidence-based studies using cannabinoids to treat epilepsy. The paper depicts the main mechanisms of action of these drugs and gives information about their efficacy and safety, as well as possible adverse events. Limitations and legal aspects are discussed. Systematic reviews and meta-analyses show that today there have been sufficient positive study results worldwide, indicating the validity of the medical use of cannabinoids. At the same time, experimental and clinical studies are needed to further investigate the mechanisms of action of cannabinoids, the characteristics of their pharmacokinetics and pharmacodynamics, efficacy and safety for many severe and disabling diseases.
About the Authors
R. G. Akzhigitov
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
Russian Federation
Renat Gayasovich Akzhigitov
43, Donskaya St., Moscow 115419
K. I. Pochigayeva
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
43, Donskaya St., Moscow 115419
Russian Federation
43, Donskaya St., Moscow 115419
F. K. Rider
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
43, Donskaya St., Moscow 115419
Russian Federation
43, Donskaya St., Moscow 115419
A. M. Teplyshova
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
43, Donskaya St., Moscow 115419
Russian Federation
43, Donskaya St., Moscow 115419
S. I. Dedayev
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
43, Donskaya St., Moscow 115419
Russian Federation
43, Donskaya St., Moscow 115419
I. A. Shpak
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
43, Donskaya St., Moscow 115419
Russian Federation
43, Donskaya St., Moscow 115419
E. V. Pashnin
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
43, Donskaya St., Moscow 115419
Russian Federation
43, Donskaya St., Moscow 115419
A. B. Gekht
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
43, Donskaya St., Moscow 115419
1, Ostrovityanov St., Moscow 117997
Russian Federation
43, Donskaya St., Moscow 115419
1, Ostrovityanov St., Moscow 117997
References
1. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614-48. doi: 10.1002/cbdv.200790144
2. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been…. Headache: J Head Face Pain. 2015;55(6):885-916. doi: 10.1111/head.12570
3. Friedman D, Sirven JI. Historical perspective on the medical use of cannabis for epilepsy: Ancient times to the 1980s. Epilepsy Behav. 2017;70(Pt B):298-301. doi: 10.1016/j.yebeh.2016.11.033
4. Touw M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs. 1981;13(1):23-34. doi: 10.1080/02791072.1981.10471447
5. Lozano I. The Therapeutic use of Cannabis sativa (L.) in Arabic medicine. J Cannabis Ther. 2001;1(1):63-70. doi: 10.1300/J175v01n01_05
6. Bonnie RJ, Whitebread CH. The Marijuana Conviction: A history of marijuana prohibition in the United States. Lindesmith Center; 1999.
7. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 1998;76(1-2):3-8. doi: 10.1016/S0304-3959(98)00033-5
8. United Nations Office on Drugs and Crime. Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol. New York: United Nations; 2013. Available at: https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/Ebook/The_International_Drug_Control_Conventions_E.pdf
9. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147 Suppl 1:S163-71. doi: 10.1038/sj.bjp.0706406
10. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics. 2015;12(4):747-68. doi: 10.1007/s13311-015-0375-5
11. Adams R, Pease DC, Clark JH. Isolation of Cannabinol, Cannabidiol and Quebrachitol from Red Oil of Minnesota Wild Hemp. J Am Chem Soc. 1940;62(8):2194-6. doi: 10.1021/ja01865a080
12. Mechoulam R, Shvo Y. Hashish I the structure of cannabidiol. Tetrahedron. 1963;19(12):2073-8. doi: 10.1016/00404020(63)85022-X
13. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86(8):1646-7. doi: 10.1021/ja01062a046
14. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc. 1971;93(1):217-24. doi: 10.1021/ja00730a036
15. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of Δ9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH). J Analyt Toxicol. 1992;16(5):283-90. doi: 10.1093/jat/16.5.283
16. Goodwin RS, Gustafson RA, Barnes A, et al. Delta(9)-tetrahydrocannabinol, 11hydroxy-delta(9)-tetrahydrocannabinol and 11nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit. 2006;28(4):545-51. doi: 10.1097/00007691200608000-00010
17. Koppel BS, Brust JCM, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-63. doi: 10.1212/WNL.0000000000000363
18. Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J Pain Palliative Care Pharmacother. 2014;28(3):216-25. doi: 10.3109/15360288.2014.941130
19. Lu Y, Anderson HD. Cannabinoid signaling in health and disease. Can J Physiol Pharmacol. 2017;95(4):311-27. doi: 10.1139/cjpp-20160346
20. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-5. doi: 10.1038/365061a0
21. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev. 2002;54(2):161-202. doi: 10.1124/pr.54.2.161
22. Quarta C, Bellocchio L, Mancini G, et al. CB1 signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metabolism. 2010;11(4):273-85. doi: 10.1016/j.cmet.2010.02.015
23. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302(5642):84-8. doi: 10.1126/science.1088208
24. Wallace MJ, Blair RE, Falenski KW, et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307(1):129-37. doi: 10.1124/jpet.103.051920
25. Gebremedhin D, Lange AR, Campbell WB, et al. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol. 1999;276(6):H2085-93. doi: 10.1152/ajpheart.1999.276.6.H2085
26. Fimiani C, Mattocks D, Cavani F, et al. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell Signal. 1999;11(3):189-93. doi: 10.1016/S0898-6568(98)00060-6
27. Guo S, Liu Y, Ma R, et al. Neuroprotective effect of endogenous cannabinoids on ischemic brain injury induced by the excess microgliamediated inflammation. Am J Transl Res. 2016;8(6):2631-40.
28. Bravo-Ferrer I, Cuartero MI, Zarruk JG, et al. Cannabinoid type-2 receptor drives neurogenesis and improves functional outcome after stroke. Stroke. 2017;48(1):204-12. doi: 10.1161/STROKEAHA.116.014793
29. Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends Pharmacol Sci. 2017;38(3):257-76. doi: 10.1016/j.tips.2016.12.003
30. Chin JH, Vora N. The global burden of neurologic diseases. Neurology. 2014;83(4):349-51. doi: 10.1212/WNL.0000000000000610
31. Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther. 2012;133(1):79-97. doi: 10.1016/j.pharmthera.2011.09.002
32. Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569-77. doi: 10.1124/jpet.109.159145
33. Hill TDM, Cascio M-G, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol. 2013;170(3):679-92. doi: 10.1111/bph.12321
34. Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21(5):344-52. doi: 10.1016/j.seizure.2012.03.001
35. Jones N, Hill A, Hill T, et al. Assessment of the anticonvulsant effects and tolerability profile of cannabidiol: GW Pharmaceuticals' Preclinical Program (P4.255). Neurology. 2015;84(14 Suppl):P4.255.
36. Dos Santos RG, Hallak JEC, Leite JP, et al. Phytocannabinoids and epilepsy. J Clin Pharm Ther. 2015;40(2):135-43. doi: 10.1111/jcpt.12235
37. Shubina L, Aliev R, Kitchigina V. Endocannabinoid-dependent protection against kainic acid-induced long-term alteration of brain oscillations in guinea pigs. Brain Res. 2017;1661:1-14. doi: 10.1016/j.brainres.2017.02.003
38. Reddy DS, Golub VM. The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther. 2016;357(1):45-55. doi: 10.1124/jpet.115.230151
39. Leo A, Russo E, Elia M. Cannabidiol and epilepsy: Rationale and therapeutic potential. Pharmacol Res. 2016;107:85-92. doi: 10.1016/j.phrs.2016.03.005
40. Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use. Dis Nerv Syst. 1967;28(7, Pt. 1):474-5.
41. Consroe PF, Wood GC, Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA. 1975;234(3):306-7. doi: 10.1001/jama.1975.03260160054015
42. Feeney DM. The marijuana window: a theory of cannabis use. Behav Biol. 1976;18(4):455-71. doi: 10.1016/S00916773(76)92488-3
43. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. 2001;42(10):1266-72. doi: 10.1046/j.1528-1157.2001.19301.x
44. Hamerle M, Ghaeni L, Kowski A, et al. Cannabis and other illicit drug use in epilepsy patients. Eur J Neurol. 2014;21(1):167-70. doi: 10.1111/ene.12081
45. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2012;(6):CD009270. doi: 10.1002/14651858.CD009270.pub2
46. Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia. 2014;55(6):787-90. doi: 10.1111/epi.12635
47. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55(6):783-6. doi: 10.1111/epi.12610
48. Saade D, Joshi C. Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report. Pediatr Neurol. 2015;52(5):544-7. doi: 10.1016/j.pediatrneurol.2015.02.008
49. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52. doi: 10.1016/j.yebeh.2015.02.043
50. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574-7. doi: 10.1016/j.yebeh.2013.08.037
51. Campbell CT, Phillips MS, Manasco K. Cannabinoids in pediatrics. J Pediatr Pharmacol Ther. 2017;22(3):176-85. doi: 10.5863/1551-6776-22.3.176
52. Mathern GW, Beninsig L, Nehlig A. Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia's survey. Epilepsia. 2015;56(1):1-6. doi: 10.1111/epi.12843
53. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791-802. doi: 10.1111/epi.12631
54. Devinsky O, Patel A, Cross J, et al. Effect of cannabidiol on drop seizures in the LennoxGastaut syndrome. N Engl J Med. 2018;378:1888-97. doi: 10.1056/NEJMoa1714631
55. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376(21):2011-20. doi: 10.1056/NEJMoa1611618
56. Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254
57. Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia. 2019;60(2):294-302. doi: 10.1111/epi.14628
58. Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia. 2018;59(8):1540-8. doi: 10.1111/epi.14477
59. Thiele E, Marsh E, MazurkiewiczBeldzinska M, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419-28. doi: 10.1111/epi.14670
60. Silvestro S, Mammana S, Cavalli E, et al. Use of cannabidiol in the treatment of epilepsy: efficacy and security in clinical trials. Molecules. 2019;24(8):1459. doi: 10.3390/molecules24081459
61. Sekar K, Pack A. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. F1000Research. 2019;8(F1000 Faculty Rev):234. doi: 10.12688/f1000research.16515.1
62. Ali S, Scheffer IE, Sadleir LG. Efficacy of cannabinoids in paediatric epilepsy. Dev Med Child Neurol. 2019;61(1):13-8. doi: 10.1111/dmcn.14087
63. Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. Longo DL, ed. N Engl J Med. 2015;373(11):1048-58. doi: 10.1056/NEJMra1407304
Review
For citations:
Akzhigitov R.G., Pochigayeva K.I., Rider F.K., Teplyshova A.M., Dedayev S.I., Shpak I.A., Pashnin E.V., Gekht A.B. The use of cannabinoids in epilepsy as an example: medical, social, and legal aspects. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):125-130. (In Russ.) https://doi.org/10.14412/2074-2711-2020-4-125-130
Views: 458
Email this article 